Holen Sie sich die Stockscreener-App
190.25
1.66%
3.10
Vorhandelsmarkt:
187.94
-2.31
-1.21%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ILMN?
Forum
Prognose
Aktiensplit
Illumina Inc Aktie (ILMN) Neueste Nachrichten
Cancer Biomarkers Market to Reach US$ 54.48 Billion by 2032 as Precision Oncology and Multi-Omics Adoption Accelerate - GlobeNewswire Inc.
Illumina expands Billion Cell Atlas alliance with Formation Bio, adds two other AI drug developers - Bitget
Illumina (ILMN) Faces German Recall Order Over Element Sequencing Patent Ruling - Yahoo Finance
Illumina Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Illumina, Inc., Formation Bio, Astrazeneca, Merck, and Eli Lilly and Company Expand Billion Cell Atlas Alliance with New Ai Drug Developers - marketscreener.com
Illumina expands Billion Cell Atlas program with new AI drug developers - marketscreener.com
Juno Bio Opens First CLIA-Certified Sequencing Lab Dedicated Entirely to Women's Health, Backed by Ada Ventures, Artesian, Illumina Accelerator, and Entrepreneur First - PR Newswire
Illumina appoints new commercial and legal officers By Investing.com - Investing.com Nigeria
Illumina price tries to gather positive momentumForecast today16-07-2026 - Economies.com
(ILMN) Risk Channels and Responsive Allocation - Stock Traders Daily
Illumina Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Illumina Inc : TD Cowen Raises Target Price t - Moomoo
Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research - AOL.com
ILMN5886317 Bond Profile — Key Metrics - TradingView
Video: Illumina gets behind the wheel to drive greater results - Illumina
Element Biosciences Prevails in German Patent Case Against Illumina - Business Wire
Illumina, Inc. Stock 12‑Month Price Target Raised to $165.72, Implies 13% Downside - TradingView
Bioinformatics Services Market Set for Strong Growth Driven - openPR.com
Illumina, Inc. Stock 12‑Month Price Target Raised to $162.94, Implies 14% Downside - TradingView
Illumina Inc. stock underperforms Friday when compared to competitors - MarketWatch
Illumina builds out C-suite with 2 new execs - MedTech Dive
Illumina Inc (ILMN) Stock Up 3.2% but GF Value Says Overvalued -- GF Score: 72/100 - GuruFocus
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina sets July 30 call on second-quarter 2026 results - Stock Titan
Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026 - marketscreener.com
Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer - Morgan County Citizen
Genomics Giant Illumina Taps Veteran Life Sciences Lawyer - Law.com
Illumina (ILMN) Is Up 6.87% in One Week: What You Should Know - Yahoo Finance
Illumina leads genomics sequencing with 90% mar... - Pluang
Illumina stock steadies as investors weigh core sequencing demand and regulatory overhang - Ad Hoc News
Illumina: While You Chased AI, This Healthcare Stock Built A $30B Moat (NASDAQ:ILMN) - Seeking Alpha
Illumina Stock Gains 43.7% in 2026: What's Powering the Rally? - Yahoo Finance
Illumina, Inc. Announces Management Appointments - marketscreener.com
Illumina Appoints Michael Sullivan and Julie Coletti to Executive Leadership Team - citybiz
Illumina appoints new commercial and legal officers - Investing.com
Illumina taps two senior leaders to steer sales and legal strategy - Stock Titan
Illumina Inc. focuses on genomics growth as a leading Nasdaq-listed life sciences company - Ad Hoc News
Align's Julie Coletti to Leave as Chief Legal and Regulatory Officer for Illumina - TradingView
Illumina (ILMN) Stock May Be 27% Undervalued Following Strong Q1 Results - Yahoo Finance
Illumina Inc. stock outperforms competitors despite losses on the day - MarketWatch
Illumina (ILMN) Jumps On Earnings And Guidance As Valuation Questions Remain - Yahoo Finance
Illumina (ILMN) Is Up 9.1% After Raising EPS Outlook On Revenue Beat Has The Bull Case Changed? - Yahoo Finance
Bifrost Biosystems Pens Agreement with Illumina for Supply of Sequencing Chemistry for Optical Pooled Screening Platform - BioSpace
Illumina, Inc. (ILMN) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Illumina (ILMN) Lifts Full Year EPS Outlook After Revenue Beat - Yahoo Finance
David P. King elected to Illumina's Board of Directors - AOL.com
Price to earnings forward of Illumina, Inc. – EUROTLX:4ILMN - TradingView
Illumina Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Illumina Inc focuses on sequencing platform innovation as investors weigh long-term growth prospects - Ad Hoc News
Life Sciences Tools & Services Stocks Q1 Results: Benchmarking Illumina (NASDAQ:ILMN) - Yahoo Finance
Illumina stock stays tied to its sequencing business. Investors watch the next filing. - Ad-hoc-news.de
Illumina Looks To Duck DNA Rival's Renewed Antitrust Case - Law360
Weekly Recap: Axelios challenges Illumina and Guggenheim lifts ILMN target to $200 - TradingView
Illumina, Inc. (ILMN) Stock Analysis: Navigating Potential Downsides Amidst 33.82% ROE - DirectorsTalk Interviews
iSeq 100 System from Illumina Inc.compact benchtop sequencer targets cost-conscious US labs - Ad-hoc-news.de
Is Illumina (ILMN) Quietly Recasting Its Clinical Genomics Strategy With Eli Lilly’s R&D Chief on Board? - simplywall.st
Illumina Inc. focuses on sequencing technology leadership as investors watch long-term growth driver - Ad-hoc-news.de
Illumina SVP Jakob Wedel Christensen sells $97,328 in stock - Investing.com
Illumina Inc. focuses on sequencing technology as investors assess long-term growth - Ad-hoc-news.de
Should You Continue to Hold ILMN Stock in Your Portfolio? - TradingView
Price to sales forward of Illumina, Inc. – NASDAQ:ILMN - TradingView
Price to book forward of Illumina, Inc. – NASDAQ:ILMN - TradingView
Enterprise value to revenue forward of Illumina, Inc. – NASDAQ:ILMN - TradingView
1.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):